Home › NCT02232191
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury. Exclusion Criteria: * Ages less than 18 and greater than 65 * Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.
About the study
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.
What is being tested
- Pneumovax-23 (biological)
Sponsor: University of California, Davis · Participants: 75 · Started: 2014-12
Contact the study team
- David V Shatz, MD · Phone: 916-734-5535
- Anthony Calabro, PhD · Phone: 916-734-4365
Official record on ClinicalTrials.gov — NCT02232191
Locations in the U.S.
| California | University of California, Davis Medical Center, Sacramento |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.